8-K: Larimar Therapeutics Announces Positive Regulatory Feedback and Reports Q4 and Full Year 2024 Financial Results

Larimar Therapeutics reports progress on its nomlabofusp program for Friedreich's ataxia, including positive FDA feedback on a potential accelerated approval pathway and a BLA submission targeted for year-end 2025.

Summary

• Larimar Therapeutics announced its fourth quarter and full year 2024 financial results and provided an update on the development of nomlabofusp for Friedreich's ataxia (FA).
• The FDA has indicated openness to considering skin frataxin (FXN) concentrations as a reasonably likely surrogate endpoint for accelerated approval.
• Larimar plans to submit a Biologics License Application (BLA) seeking accelerated approval by the end of 2025.
• A global Phase 3 study is planned to initiate in mid-2025, with feedback obtained from both the FDA and EMA on the study protocol.
• Topline data from the OLE study and the adolescent cohort of the PK run-in study are expected in September 2025.
• The company's cash, cash equivalents, and marketable securities totaled $183.5 million as of December 31, 2024, providing a cash runway into the second quarter of 2026.
• The net loss for the fourth quarter of 2024 was $28.8 million, or $0.45 per share, compared to a net loss of $13.0 million, or $0.30 per share, for the fourth quarter of 2023.
• The net loss for the full year 2024 was $80.6 million, or $1.32 per share, compared to a net loss of $36.9 million, or $0.84 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the FDA's openness to considering skin FXN concentration as a surrogate endpoint and the company's progress towards a BLA submission. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• FDA's openness to considering skin FXN concentration as a surrogate endpoint could expedite the approval process.
• The company has a strong cash position of $183.5 million, providing a runway into the second quarter of 2026.
• The global Phase 3 study is on track to initiate in mid-2025, following feedback from both the FDA and EMA.
• The FDA accepted the transition to a lyophilized form of nomlabofusp, which is intended for commercialization.
• The OLE study continues to advance, with some participants on daily treatment for up to one year.

Negatives

• The company reported a net loss of $80.6 million for the full year 2024, significantly higher than the $36.9 million loss in 2023.
• Research and development expenses increased substantially, primarily due to increased manufacturing costs for nomlabofusp.
• The OLE protocol has been amended to include premedication to reduce the risk of allergic reactions, including anaphylaxis.

Risks

• The FDA may not ultimately accept skin FXN concentration as a surrogate endpoint.
• Clinical trial results may differ from earlier non-clinical and clinical data.
• Delays in patient recruitment could impact the timeline for clinical trials.
• The company's ability to raise additional capital is subject to market conditions and other factors.
• The success of nomlabofusp depends on obtaining regulatory approvals and successfully commercializing the product.

Future Outlook

Larimar is focused on advancing the nomlabofusp program, with a BLA submission targeted for the end of 2025 and the initiation of a global Phase 3 study in mid-2025. The company believes its near-term data package strongly positions it to bring the first potential disease-modifying therapy to patients with FA.

Management Comments

• Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar, stated that the FDA's recommendations are in line with the company's current approach and that they appreciate the frequent dialogue via the START pilot program.
• Dr. Ben-Maimon noted that the OLE study continues to advance, with some participants on daily treatment for up to one year, and that the 25 mg initial data showed increased and sustained FXN levels over time and early trends in improved clinical outcomes.

Industry Context

Larimar Therapeutics is developing nomlabofusp as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease with limited treatment options. The company's focus on addressing the underlying frataxin deficiency and its participation in the FDA's START pilot program highlight its commitment to advancing innovative therapies for rare diseases.

Comparison to Industry Standards

• Biogen's Omaveloxolone (SKYCLARYS) is an approved therapy for Friedreich's ataxia, but it focuses on modifying mitochondrial oxidative stress rather than directly replacing the deficient frataxin protein, setting nomlabofusp apart as a potential first-in-class protein replacement therapy.
• PTC Therapeutics is developing Vatiquinone, a 15-Lipoxygenase Inhibitor, currently in Phase III trials for FA, representing another approach to managing the disease by targeting inflammation.
• Lexeo Therapeutics is pursuing a gene therapy approach with LX2006, aiming for frataxin gene replacement, which is in Phase I/II trials, indicating a longer-term, potentially curative strategy compared to Larimar's protein replacement approach.
• Design Therapeutics is working on DT-216P2, a GeneTAC that regulates gene expression, in the preclinical stage, suggesting a different mechanism of action focused on modulating gene expression related to FA.

Stakeholder Impact

• Shareholders may react positively to the potential for accelerated approval and the company's strong cash position.
• Patients with Friedreich's ataxia could benefit from a potential new treatment option.
• Employees are likely to be impacted by the company's ongoing research and development efforts.

Next Steps

• Continue discussions with the FDA regarding the adequacy of the safety data set to support the BLA submission.
• Initiate the global Phase 3 study in mid-2025.
• Complete dosing of study participants in the adolescent PK run-in cohort by the end of March 2025.
• Introduce the lyophilized dosage form into clinical studies in mid-2025.
• Provide an update on OLE data in September 2025.
• Submit the BLA seeking accelerated approval by year-end 2025.

Key Dates

Keywords

nomlabofusp, Friedreich's ataxia, FXN, accelerated approval, clinical trials, BLA, Larimar Therapeutics, rare diseases, biotechnology